Immunology and Microbiology
Keratinocyte
44%
T Cell
41%
Tumor Necrosis Factor
34%
Dermatitis
29%
Psoriatic Arthritis
26%
Mitogen
22%
Secukinumab
20%
Adalimumab
18%
Mouse
17%
Cytokine
16%
Staphylococcus Aureus
16%
Imiquimod
16%
Arthritis Mutilans
14%
Interleukin 17
14%
Biological Product
13%
Enterotoxin
13%
Atopic Dermatitis
12%
Signal Transduction
12%
Ustekinumab
12%
Prevalence
10%
Mouse Model
10%
Gene Expression
9%
Coronary Artery
8%
Interleukin 20
8%
Comorbidity
8%
Knockout Mouse
8%
Wild Type Mouse
8%
down Regulation
7%
Normal Human
7%
Quantitative Reverse Transcription Polymerase Chain Reaction
7%
STAT3
7%
P53
6%
Tumor Necrosis Factor Alpha
6%
CCL20
6%
Binding Site
5%
Gene Expression Profiling
5%
Inflammatory Cytokine
5%
Heat Shock
5%
Proinflammatory Cytokine
5%
Real-Time Polymerase Chain Reaction
5%
Inflammation Response
5%
Inflammatory Disorder
5%
Inflammatory Cell
5%
Pharmacology, Toxicology and Pharmaceutical Science
Psoriasis
100%
Psoriasis Vulgaris
38%
Cutaneous T Cell Lymphoma
24%
Psoriatic Arthritis
23%
Disease
22%
Secukinumab
19%
Biological Product
18%
Staphylococcus Aureus
13%
Tumor Necrosis Factor
12%
Calcipotriol
12%
Interleukin 17
11%
Dermatitis
11%
Brodalumab
11%
Betamethasone Dipropionate
11%
Staphylococcus Enterotoxin
10%
Biological Marker
9%
Ustekinumab
9%
Syndrome
9%
Disease Exacerbation
9%
Antipsoriasis Agent
8%
Inflammation
8%
Methotrexate
8%
Atopic Dermatitis
7%
Prevalence
7%
Disease Activity
7%
Cohort Study
7%
Enterotoxin
6%
Adverse Event
6%
microRNA 155
6%
Tofacitinib
6%
Comorbidity
6%
Cytokine
5%
Antiinflammatory Agent
5%
Ixekizumab
5%
Nitrogen Mustard
5%
12-O-Tetradecanoylphorbol-13-Acetate
5%
Tildrakizumab
5%
Mycosis fungoides
5%
Tumor Necrosis Factor Inhibitor
5%
Clinical Trial
5%
Mouse
5%
Medicine and Dentistry
Psoriasis
90%
Mycosis fungoides
26%
Disease
20%
Psoriasis Vulgaris
19%
Cutaneous T Cell Lymphoma
14%
Psoriasis Area and Severity Index
14%
Cohort Analysis
13%
Biological Product
13%
Psoriatic Arthritis
13%
Quality of Life
12%
microRNA
12%
Topical Treatment
9%
Disease Exacerbation
9%
Total Skin Electron Therapy
8%
Parapsoriasis
8%
Climatotherapy
8%
T Cell
8%
Biological Marker
8%
Dermatology
8%
Atopic Dermatitis
7%
Inflammatory Disorder
7%
Tumor Necrosis Factor
7%
Patient-Reported Outcome
6%
Dermatosis
6%
Chlormethine
5%
Rheumatology
5%
Systematic Review
5%
Staphylococcus Aureus
5%
Ixekizumab
5%
Secukinumab
5%
Dermatology Life Quality Index
5%
microRNA 155
5%
Betamethasone Dipropionate
5%
Calcipotriol
5%
Patient Preference
5%
